Findings

What do systematic reviews say?

47 questions · 48 findings · 7 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 15 · 31.3%GRADE not reported 0 · 0%Very low 4 · 8.3%Low 19 · 39.6%Moderate 10 · 20.8%High 0 · 0%

Low molecular weight heparin vs UFH

Incidence of recurrent VTE1 after initial treatment (up to 15 days) · patients with venous thromboembolism.

LMWH probably leads to lower incidence of recurrent VTE1 after initial treatment (up to 15 days) compared with UFH (moderate certainty).

1 finding from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.69 [0.49, 0.98]
18 studies · 6238 participants
Moderate

Low molecular weight heparin vs UFH

Recurrent VTE · patients with venous thromboembolism.

LMWH probably leads to lower incidence of recurrent VTE1 (3 months compared with UFH (moderate certainty).

2 findings from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.71 [0.56, 0.9]
16 studies · 6661 participants
Moderate
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.72 [0.59, 0.88]
22 studies · 9489 participants
Moderate

Low molecular weight heparin vs UFH

Reduction in thrombus size (pre‐ and post‐treatment venograms) · patients with venous thromboembolism.

LMWH may leads to lower reduction in thrombus size (pre‐ and post‐treatment venograms) compared with UFH (low certainty).

1 finding from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.71 [0.61, 0.82]
16 studies · 2909 participants
Low

Low molecular weight heparin vs UFH

Major bleeding · patients with venous thromboembolism.

LMWH probably leads to lower incidence of major haemorrhagic episodes (during initial treatment ‐… compared with UFH (moderate certainty).

1 finding from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.69 [0.5, 0.95]
25 studies · 8780 participants
Moderate

Low molecular weight heparin vs UFH

Overall mortality (end of · patients with venous thromboembolism.

LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).

1 finding from 1 review

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial… 2017 · Cochrane Headline outcomes only
OR 0.84 [0.7, 1.01]
24 studies · 9663 participants
Moderate

Intervention not reported

HIT in people undergoing major surgical procedures · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days

The intervention may leads to lower HIT in people undergoing major surgical procedures (low certainty).

1 finding from 1 review

Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in… 2017 · Cochrane Headline outcomes only
RR 0.22 [0.06, 0.75]
2 studies · 586 participants
Low

Intervention not reported

HIT complicated by venous thromboembolism · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days

The intervention may leads to lower HIT complicated by venous thromboembolism (low certainty).

1 finding from 1 review

Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in… 2017 · Cochrane Headline outcomes only
RR 0.22 [0.06, 0.84]
3 studies · 1398 participants
Low